OBALON THERPTCS logoObalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Devices & Implants
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OBLN
  • CUSIP: N/A
  • Web: www.obalon.com
  • Market Cap: $152.59 million
  • Outstanding Shares: 16,824,000
Average Prices:
  • 50 Day Moving Avg: $9.77
  • 200 Day Moving Avg: $9.77
  • 52 Week Range: $8.27 - $14.57
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.98 million
  • Price / Sales: 30.64
  • Book Value: $2.98 per share
  • Price / Book: 3.04
  • EBITDA: ($27,120,000.00)
  • Net Margins: -566.87%
  • Return on Equity: -108.07%
  • Return on Assets: -48.50%
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 13.29%
  • Quick Ratio: 13.14%
  • Average Volume: 43,407 shs.
  • Short Ratio: 23.88

Frequently Asked Questions for OBALON THERPTCS (NASDAQ:OBLN)

What is OBALON THERPTCS's stock symbol?

OBALON THERPTCS trades on the NASDAQ under the ticker symbol "OBLN."

How were OBALON THERPTCS's earnings last quarter?

OBALON THERPTCS (NASDAQ:OBLN) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.03. The company earned $1.96 million during the quarter, compared to analysts' expectations of $1.77 million. OBALON THERPTCS had a negative return on equity of 108.07% and a negative net margin of 566.87%. View OBALON THERPTCS's Earnings History.

When will OBALON THERPTCS make its next earnings announcement?

OBALON THERPTCS is scheduled to release their next quarterly earnings announcement on Friday, November, 10th 2017. View Earnings Estimates for OBALON THERPTCS.

Where is OBALON THERPTCS's stock going? Where will OBALON THERPTCS's stock price be in 2017?

4 analysts have issued 1 year price objectives for OBALON THERPTCS's stock. Their forecasts range from $6.00 to $20.00. On average, they expect OBALON THERPTCS's stock price to reach $15.25 in the next twelve months. View Analyst Ratings for OBALON THERPTCS.

What are analysts saying about OBALON THERPTCS stock?

Here are some recent quotes from research analysts about OBALON THERPTCS stock:

  • 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (8/16/2017)
  • 2. Northland Securities analysts commented, "We are initiating coverage of Obalon Therapeutics with an Underperform rating / $6 PT. We are concerned that forward estimates are too high, the science is unclear, the logistical issues of 3- intragastric balloon (IGB) procedures remain, and finally, ponying up $8,000 or so in a cash-pay procedure for a 15 lb. weight loss makes this product more suitable for a wealthy, event-driven" motivated patient, therefore making the realistic TAM quite small." (6/21/2017)
  • 3. Canaccord Genuity analysts commented, "We reiterate our BUY rating following marketing meetings with management. We recently hosted two days of upbeat investor meetings with Obalon CEO Andy Rasdal as well as CFO Bill Plovanic. We came away from those meetings with a clearer understanding of investor sentiment as well as early commercial traction in the US launch." (5/18/2017)

Who are some of OBALON THERPTCS's key competitors?

Who are OBALON THERPTCS's key executives?

OBALON THERPTCS's management team includes the folowing people:

  • Kim P Kamdar, Chairman of the Board
  • Andrew Rasdal, President, Chief Executive Officer, Director
  • William J. Plovanic, Chief Financial Officer
  • Kelly Huang Ph.D., Chief Operating Officer
  • Nooshin Hussainy, Vice President - Finance
  • Steve Johnson, Vice President - Operations
  • Matthew Norwood, Vice President of Sales
  • Lisa Metzner, Vice President of Marketing
  • Amy VandenBerg, Vice President - Regulatory and Clinical Affairs
  • Donald Young, Vice President of Quality Assurance


(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy OBALON THERPTCS stock?

Shares of OBALON THERPTCS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OBALON THERPTCS's stock price today?

One share of OBALON THERPTCS stock can currently be purchased for approximately $9.07.

MarketBeat Community Rating for OBALON THERPTCS (NASDAQ OBLN)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about OBALON THERPTCS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OBALON THERPTCS (NASDAQ:OBLN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $15.25 (68.14% upside)
Consensus Price Target History for OBALON THERPTCS (NASDAQ:OBLN)
Price Target History for OBALON THERPTCS (NASDAQ:OBLN)
Analysts' Ratings History for OBALON THERPTCS (NASDAQ:OBLN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/2/2017Northland SecuritiesReiterated RatingSell$6.00MediumView Rating Details
5/18/2017Canaccord GenuityReiterated RatingBuyLowView Rating Details
3/19/2017BTIG ResearchReiterated RatingBuy$20.00MediumView Rating Details
10/31/2016Stifel NicolausInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings by Quarter for OBALON THERPTCS (NASDAQ:OBLN)
Earnings History by Quarter for OBALON THERPTCS (NASDAQ OBLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017($0.43)N/AView Earnings Details
8/2/2017Q2 2017($0.43)($0.46)$1.77 million$1.96 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.33)($0.47)$1.60 million$1.47 millionViewN/AView Earnings Details
11/11/2016Q3 2016($0.32)($5.46)$0.70 million$0.77 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for OBALON THERPTCS (NASDAQ:OBLN)
Current Year EPS Consensus Estimate: $-1.86 EPS
Next Year EPS Consensus Estimate: $-1.65 EPS


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OBALON THERPTCS (NASDAQ:OBLN)
Insider Ownership Percentage: 16.40%
Institutional Ownership Percentage: 44.97%
Insider Trades by Quarter for OBALON THERPTCS (NASDAQ:OBLN)
Institutional Ownership by Quarter for OBALON THERPTCS (NASDAQ:OBLN)
Insider Trades by Quarter for OBALON THERPTCS (NASDAQ:OBLN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/12/2016Kim P KamdarDirectorBuy13,400$15.00$201,000.00View SEC Filing  
10/12/2016Matthew NorwoodVPBuy1,000$15.00$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Loading headlines, please wait.



OBALON THERPTCS (OBLN) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.